About Cutera (NASDAQ:CUTR)
Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin rejuvenation. In addition, the company offers GenesisPlus system, a laser product for use in the temporary increase of clear nails in patients with onychomycosis, as well as for the treatment of fine wrinkles, diffuse redness, and rosacea; and CoolGlide, as well as myQ, a third-party sourced system for the Japanese market. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Electromedical equipment
SectorComputer and Technology
Trailing P/E Ratio57.66
Forward P/E Ratio77.89
Sales & Book Value
Annual Sales$151.49 million
Price / Sales3.99
Cash Flow$0.9054 per share
Price / Cash49.04
Book Value$4.68 per share
Price / Book9.49
EPS (Most Recent Fiscal Year)$0.77
Net Income$29.99 million
Return on Equity16.12%
Return on Assets9.87%
Cutera (NASDAQ:CUTR) Frequently Asked Questions
What is Cutera's stock symbol?
Cutera trades on the NASDAQ under the ticker symbol "CUTR."
How will Cutera's stock buyback program work?
Cutera announced that its board has authorized a share repurchase program on Tuesday, August 8th 2017, which authorizes the company to buyback $25,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board believes its stock is undervalued.
How were Cutera's earnings last quarter?
Cutera, Inc. (NASDAQ:CUTR) posted its earnings results on Tuesday, May, 8th. The medical device company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.03. The medical device company earned $34.10 million during the quarter, compared to the consensus estimate of $35.27 million. Cutera had a return on equity of 16.12% and a net margin of 18.54%. The firm's quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.07) earnings per share. View Cutera's Earnings History.
When is Cutera's next earnings date?
What guidance has Cutera issued on next quarter's earnings?
Cutera issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $1.03-1.11 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.05. The company issued revenue guidance of $178-181 million, compared to the consensus revenue estimate of $179.02 million.
What price target have analysts set for CUTR?
6 equities research analysts have issued 1 year price targets for Cutera's shares. Their forecasts range from $32.00 to $60.00. On average, they expect Cutera's stock price to reach $45.40 in the next year. View Analyst Ratings for Cutera.
What are Wall Street analysts saying about Cutera stock?
Here are some recent quotes from research analysts about Cutera stock:
- 1. According to Zacks Investment Research, "Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. " (4/18/2018)
- 2. Gabelli analysts commented, "As a leading laser dermatology company, Cutera is an attractive long-term investment as management focuses on execution, growing sales and improving operating performance. Throughout 2017, Cutera revamped several members of its management team, including its CEO and CFO, along with several new hires to build out its sales and operational infrastructure in the US and internationally. Management is putting in place new processes to improve upon product development and scale up its organization for sustainable growth." (2/16/2018)
- 3. Maxim Group analysts commented, "3Q17 total revenue of $38.2M, up 26.1% y/y, was above both our estimate of $35.6M and consensus of $34.7M. North America product revenue grew 57.4% y/y, while international product revenue grew just 0.1% y/y." (11/8/2017)
Who are some of Cutera's key competitors?
Some companies that are related to Cutera include CONMED (CNMD), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), BioLife Solutions (BLFS), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Viveve Medical (VIVE), Zynex Inc. common stock (ZYXI), Edap Tms (EDAP) and Semler Scientific (SMLR).
Who are Cutera's key executives?
Cutera's management team includes the folowing people:
- Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 47)
- Mr. Ronald J. Santilli, Exec. Officer (Age 58)
- Mr. James A. Reinstein, CEO, Pres & Director (Age 53)
- Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 52)
- Dr. Michael Karavitis Ph.D., Exec. VP & Chief Technology Officer
Has Cutera been receiving favorable news coverage?
News coverage about CUTR stock has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cutera earned a media sentiment score of 0.18 on Accern's scale. They also assigned media stories about the medical device company an impact score of 45.04 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Cutera's major shareholders?
Cutera's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.21%), Gamco Investors INC. ET AL (4.20%), Dimensional Fund Advisors LP (4.17%), Gabelli Funds LLC (2.74%), Teton Advisors Inc. (2.27%) and Northern Trust Corp (1.59%). Company insiders that own Cutera stock include David A Gollnick, David B Apfelberg, Gregory A Barrett, J Daniel Plants, James A Reinstein, Larry Laber, Miguel Pardos, Ronald J Santilli and Timothy J Oshea. View Institutional Ownership Trends for Cutera.
Which major investors are selling Cutera stock?
CUTR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Granite Investment Partners LLC, Dimensional Fund Advisors LP, Spark Investment Management LLC, DE Burlo Group Inc., Credit Agricole S A and Citigroup Inc.. Company insiders that have sold Cutera company stock in the last year include David A Gollnick, David B Apfelberg, James A Reinstein, Larry Laber, Miguel Pardos, Ronald J Santilli and Timothy J Oshea. View Insider Buying and Selling for Cutera.
Which major investors are buying Cutera stock?
CUTR stock was purchased by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Mackay Shields LLC, Carillon Tower Advisers Inc., Cortina Asset Management LLC, KBC Group NV, Millennium Management LLC, Old Mutual Global Investors UK Ltd. and WINTON GROUP Ltd. Company insiders that have bought Cutera stock in the last two years include Gregory A Barrett and James A Reinstein. View Insider Buying and Selling for Cutera.
How do I buy shares of Cutera?
Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cutera's stock price today?
One share of CUTR stock can currently be purchased for approximately $44.40.
How big of a company is Cutera?
Cutera has a market capitalization of $591.74 million and generates $151.49 million in revenue each year. The medical device company earns $29.99 million in net income (profit) each year or $0.77 on an earnings per share basis. Cutera employs 367 workers across the globe.
How can I contact Cutera?
Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected]
MarketBeat Community Rating for Cutera (CUTR)MarketBeat's community ratings are surveys of what our community members think about Cutera and other stocks. Vote "Outperform" if you believe CUTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUTR will underperform the S&P 500 over the long term. You may vote once every thirty days.